Avenna
Culham, United Kingdom
Chronic inflammatory diseases (cIDs) are driven by chronic inflammation (cI), which is invisible to medics. Our biomarker technology will transform cID medicine and drug development by making cI both visible and quantifiable. It does so by measuring biomolecular patterns of cI processes in finger-prick samples of blood. Our Immunofrailty Tests ( IFT), render chronic inflammation (cI), which drives immune disorders, visible and quantifiable. The tests are members of our GlyHealth IVD platform.
Company Info
- Founded
- 2017
- Website
- avenna.com/
Only accessible to MedStartr community members.
Join nowWhat do you think of Avenna?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.